Cylex Announces Significant Expansions and Reassignments of Personnel
COLUMBIA, Md., Aug. 21 /PRNewswire/ — Cylex(TM) is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology. Cylex is seeing continuing growth of its first marketed product, the ImmuKnow(R) assay for detection of cell-mediated immunity, and the Company believes that this product and the Company itself have still greater potential.
“The ability to fully support the needs of our customers is critical to the development of this company as a provider of diagnostic tests focused on the immune system,” said Mr. Brad Stewart, the president of Cylex. “We have therefore made a series of key appointments designed primarily to address customer needs, and I am pleased to be able to announce these today.”
— Sharlene P. Blum has come to Cylex in the new position of Director, Customer Care. She had most recently held institutional and patient quality and service management positions with Quest Diagnostics. Ms. Blum is a results-oriented operations leader with over 20 years of experience in laboratory services operations management. She has also been awarded a Six Sigma Black Belt in project management.
— Genesis E. Cautivar has joined the Company as a Laboratory Account Manager in the Customer Care group. He was previously a technical field specialist with Siemens Medical Solutions, where he focused on products used in the hematology marketplace.
— Linyi Zhang has joined Cylex as Manager, Clinical Affairs. In this position she will focus on clinical trials of Cylex’s current and development-stage products. She has over 20 years experience in biomedical research, assay development, product development, and clinical study in both academia and industry. Most recently, she was a clinical trials specialist with the National Institutes of Health. Prior to that she held various positions at Human Genome Sciences.
In addition, Cylex has appointed four new Business Development Managers, who will have regional field responsibilities for current and target customers in specific areas of the USA:
— Hilary A. Comfort has previously held account management and sales positions with several well-known pharmaceutical and biotechnology companies, most recently including UCB Pharma and Astellas.
— William T. Futch has come to the company from Zimmer Dental, where he was a territory manager, after additional prior field experience with Pfizer.
— Greg Nabors brings over 15 years of field sales experience with leading pharmaceutical companies, including Aventis, Knoll Pharmaceutical and Wyeth-Ayerst Laboratories.
— Eric G. Gann has been with Cylex since 2005 as a Laboratory Liaison and Laboratory Account Manager in the Customer Care group, and will be taking on this new role in business development.
ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.
The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.
About Cylex, Inc.
Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products intended to illuminate immunity. The Company’s patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. The Company is based in Columbia, MD, USA.
CONTACT: Lynn Shepherd, +1-267-250-7378, firstname.lastname@example.org, orKetura Lispi, +1-215-925-9901, email@example.com, both of Vox Medica, Inc,for Cylex, Inc.